JBM (Healthcare) Limited Just Recorded A 20% EPS Beat: Here's What Analysts Are Forecasting Next
It's been a good week for JBM (Healthcare) Limited (HKG:2161) shareholders, because the company has just released its latest yearly results, and the shares gained 8.3% to HK$2.74. Revenues were HK$782m, approximately in line with whatthe analyst expected, although statutory earnings per share (EPS) crushed expectations, coming in at HK$0.24, an impressive 20% ahead of estimates. The analyst typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analyst has changed their mind on JBM (Healthcare) after the latest results.
Taking into account the latest results, the current consensus from JBM (Healthcare)'s lone analyst is for revenues of HK$925.7m in 2026. This would reflect a decent 18% increase on its revenue over the past 12 months. Per-share earnings are expected to step up 19% to HK$0.29. Yet prior to the latest earnings, the analyst had been anticipated revenues of HK$930.8m and earnings per share (EPS) of HK$0.23 in 2026. Although the revenue estimates have not really changed, we can see there's been a great increase in earnings per share expectations, suggesting that the analyst has become more bullish after the latest result.
See our latest analysis for JBM (Healthcare)
The consensus price target rose 29% to HK$3.11, suggesting that higher earnings estimates flow through to the stock's valuation as well.
Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. The period to the end of 2026 brings more of the same, according to the analyst, with revenue forecast to display 18% growth on an annualised basis. That is in line with its 18% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 8.6% per year. So although JBM (Healthcare) is expected to maintain its revenue growth rate, it's definitely expected to grow faster than the wider industry.
The Bottom Line
The most important thing here is that the analyst upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards JBM (Healthcare) following these results. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was also a nice increase in the price target, with the analyst clearly feeling that the intrinsic value of the business is improving.
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At least one analyst has provided forecasts out to 2028, which can be seen for free on our platform here.
We also provide an overview of the JBM (Healthcare) Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.